Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Apr 05, 2021 12:09pm
68 Views
Post# 32937379

RE:RE:RE:RE:RE:RE:RE:RE:Cytodyn -financing

RE:RE:RE:RE:RE:RE:RE:RE:Cytodyn -financingNaw...we want the facts -- the facts that will come from these human trials -- to clearly underpin a much higher valuation that will be entierly justified.  Maybe even we get to overvalued territory as excitement over commercialization prospects propel it.

Yes, it isn't valued what we think it should be based on some other legitimate comps, but I think the facts will get us there and more, soon. I realize you're probably being sarcastic as all pumps eventually get dumped.

scarlet1967 wrote: Hire their whole IR department, whether we like it or not their investor relation strategy has worked, their short interest is high yes! there are law suits pending yes! but we can't ignore the fact they have successfully managed to pump their valuation with much less so yes pump the deflated valuation of THTX please, giving the undervaluation of the company it's almost unethical, unfair not to PUMP the valuation.


Wino115 wrote: Not to rub salt in our wounds, by CYDY is actually up 20% on their news.

palinc2000 wrote: Everytime I revisit the OO the worst it looks,,,,Awful timing ,terrible  terms ,unimaginative , permanent long term damage to long term shareholders ,,,




Wino115 wrote: Hire their CFO, he understands a fleece   ;)


palinc2000 wrote: They did the deal with only ONE instutition,,,,,,,,,,The deal is definitely much better for CYDY and shareholdsc in spite of the high interest rate than TH s deal ,,,....which cost tens of millions to sharehoders due to dilution amd which will cost  possibly tens of millions with the exercise of the warrants


SPCEO1 wrote: That is a really ugly interest rate on that CYDY convert but given the crazy high strike price, I think you could argue it was a better deal than the OO. 
The Odious Offering was a historically bad deal. I have been at the investing game for 42 years and it was certainly one of the worst i have ever seen. One aspect of the deal that was a head scratcher was the warrants not coming due until after the convertible comes due. If you were going to offer such outlandishly attractive terms on the warrant, why not then have it come due before the convertible in case you need the extra money.to pay off the convert? I think Palin may have pointed this out previously, but it is just another boneheaded aspect of the OO. That being said, if I understand it correctly, the warrants do not trade so you can only access the cash tied up in the warrant by exercising them. So, my guess is that each quarter going forward (2Q21 and onward), we may see some small amount of them convert as the only way someone can get actual money out of the warrant is to exercise them and then sell the shares. While institutional investors in the deal will likely be holding onto those warrants until maturity, retail investors may just want to turn them into cash sooner rather than later as they likely are not fully aware of what they own and they probably will not like something sitting on their account statement without ever moving higher (I assume they would be priced at zero on customer statements since there is no trading in them). So, I would not be surprised if they picked up small amounts of new equity capital most quarters as some warrants convert into equity just to be able to get at the cash tied up in them.

Given all the hiring they are doing, they may need the extra cash!

Wino115 wrote: I looked at your link just to see what amazingly high interest rate they paid.  I was surprised to see whomever the buyer is only gets 10% interest! Money's cheap these days I guess....  and with a strike price massively out of the money (3x of current price) at a level the share's never seen! Cheap money indeed.


 

 

 

 

 

 




<< Previous
Bullboard Posts
Next >>